Eximo was established by Accelmed in 2012, under the Targeted Innovation model framework, and Dr. (NASDAQ: ANGO), for $66 million ( $46 million upfront and $20 pursuant to achieving milestones). Accelmed accomplished several exits to date, the most recent being that of Eximo Medical, its portfolio company based in Rehovot, Israel, which was purchased by AngioDynamics Inc. The new fund is being launched in parallel to the fruition of portfolio companies in Accelmed Ventures I, the Group's current venture capital fund, which was established in 2011 by Uri Geiger and Mori Arkin together with Migdal Group. This is the fourth fund established by the Accelmed group, which currently manages over $300 million through Accelmed Ventures and the private equity fund, Accelmed Partners. led by the British businessman Vincent Tchenguiz. Uri Geiger, Founder and Managing Partner at Accelmed, will head the investment committee of the new fund, which has already received a commitment from an anchor investor, Consensus Business Group Ltd. Irit Yaniv and Amir Blatt, both partners at Accelmed, will invest in Israeli and global pre-revenue healthtech startups, including medical devices and digital health. 7, 2019 /PRNewswire/ - Accelmed, a group of funds investing in healthtech companies in the fields of medical device and digital health, announced today that it is establishing Accelmed Ventures II, a new venture capital fund with the goal of raising and managing approximately $100 million. It was a significant milestone for us to show B-Laser’s ability to cross a highly calcified lesion using the step-by-step technique without the need to cross with a wire first in very challenging scenarios (including long and severely calcific lesions),” said Yoel Zabar, CEO of Eximo Medical.HERZLIYA, Israel, Oct. We continue to leverage the inherent advantages of our unique short pulse 355nm laser platform to develop novel techniques and expand our system’s utilization and market opportunity. “Eximo is extremely excited with the current commercial progress the B-Laser is experiencing in the competitive U.S. The B-Laser has so far been used to treat patients who have highly complex, highly calcified lesions above and below the arterial segments in the knee. I am very proud to be part of this exciting technology and journey.” “The capability to cross chronically occluded arteries without needing to cross with a wire first, and to then be able to perform atherectomy over a wire by using the same catheter represents a welcomed and significant addition to our toolkit as it addresses a real unmet need in our practice. Luis Leon, a clinician that has begun using the B-Laser system to treat patients, in a press release. I am very excited to work with Eximo using the B-Laser in a variety of PAD patients and to incorporate it routinely in our outpatient-based laboratory,” said Dr.
“There is a well-known paucity of devices that allows interventionists to cross occlusive lesions in an intraluminal path as opposed to sub-intimal. Eximo’s On-Line Photo-Acoustic Signal Monitoring was also implemented for the first time during the study and showed that machine learning can help interventionists characterize materials that are in contact with catheter tips while also providing a warning signal to prevent vessel injury and procedural complications. The step-by-step crossing approach uses a standard B-Laser catheter followed by the atherectomy using the same catheter that is used with standard guidewires.ĭuring a Polish study, the B-Laser system was successful without complications, including in long and severely calcified lesions. The system was launched in a step-by-step approach for therapy in patients who have highly complex, arterial occlusive peripheral arterial disease. Eximo Medical has recently launched its B-Laser Atherectomy System for patients who have arterial occlusive peripheral arterial disease.
0 kommentar(er)
